RGNX Stock Risk & Deep Value Analysis
Regenxbio Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on RGNX
We analyzed Regenxbio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RGNX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
RGNX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
About Regenxbio Inc (RGNX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$615.77M
RGNX Deep Value Analysis
RGNX Red Flags & Warning Signs
- âš
Complete Response Letter (CRL) from FDA for RGX-314 BLA
- âš
Unexpected Safety Signals Emerging from Post-Marketing Surveillance or Clinical Trials
- âš
Intensified Competition from Novel Anti-VEGF or Gene Therapy Approaches
- âš
Higher-than-expected cash burn leading to further dilution
Unlock RGNX Red Flags & Risk Warnings
Create a free account to see the full analysis
RGNX Financial Health Metrics
Market Cap
$615.77M
RGNX Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat will persist due to the proprietary nature of the NAV platform, which allows for consistent and high-yield manufacturing, and the significant intellectual property surrounding specific gene therapy constructs. The high capital investment and regulatory expertise required to bring a gene therapy to market also create substantial barriers to entry. Durability is tied to successful product launches and continued pipeline innovation.
RGNX Competitive Moat Analysis
Sign up to see competitive advantages
RGNX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •BLA Acceptance by FDA (Q1 2026)
- •Q4 2025 Earnings Report and Pipeline Update (Expected Late Feb/Early March 2026)
- •PDUFA Target Date Announcement (Post-BLA Acceptance)
Medium-Term (6-18 months)
- •RGX-314 FDA Approval Decision (PDUFA Action Date, likely Q4 2026/Q1 2027)
- •Initial Commercial Launch Preparation and Manufacturing Scale-up for RGX-314 (Post-Approval)
- •Updates on other pipeline assets (e.g., RGX-202 for Duchenne)
Long-Term (18+ months)
- •RGX-314 Achieving Multi-Billion Dollar Peak Sales for Wet AMD
- •Successful Expansion of NAV Platform to Additional Indications (e.g., Diabetic Retinopathy, Rare Diseases)
- •Industry Disruption by One-Time Gene Therapy Modalities
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
RGNX Bull Case: What Could Go Right
- ✓
FDA PDUFA approval for RGX-314 and label details.
- ✓
Initial sales trajectory and market penetration rates post-RGX-314 launch.
- ✓
Updates on other gene therapy programs utilizing the NAV platform (e.g., RGX-202).
- ✓
Cash burn rates and any potential equity raises.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
